DK2364360T3 - Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents
Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf Download PDFInfo
- Publication number
- DK2364360T3 DK2364360T3 DK09756431.4T DK09756431T DK2364360T3 DK 2364360 T3 DK2364360 T3 DK 2364360T3 DK 09756431 T DK09756431 T DK 09756431T DK 2364360 T3 DK2364360 T3 DK 2364360T3
- Authority
- DK
- Denmark
- Prior art keywords
- tablet formulation
- weight
- pharmaceutical tablet
- antisense oligonucleotide
- approx
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Claims (19)
1. Farmaceutisk tabletformulering til oral administration af et antisense-oligonukleotid omfattende: en intra-granulær fase omfattende et antisense-oligonukleotid vist med SEQ ID NO 1 eller et farmaceutisk acceptabelt salt deraf og et farmaceutisk acceptabelt fyldstof; en ekstra-granulær fase omfattende et disintegrant; og en enterisk coating omfattende en ethylacrylat-methacrylsyre-copolymer, hvor når den testet i et USP/EP Type 2-apparat (skovl) ved 100 omdr/min og 37°C i en phosphatbuffer med en pH på 6,6 ikke mere end ca. 50% af mængden af antisense-oligonukleotidet frigives fra den farmaceutiske tabletformulering over en periode på 30 minutter og når testet i et USP/EP Type 2-apparat (skovl) ved 100 omdr/min og 37°C i fortyndet HCI med en pH på 1,0 i det væsentlige intet af mængden af antisense-oligonukleotidet frigives fra den farmaceutiske tabletformulering over en periode på 120 minutter, og hvor formuleringen leverer antisense-forbindelsen til slutileum og højre tyktarm på en patient.
2. Farmaceutisk tabletformulering ifølge krav 1, hvor internukleotidbindinger af SEQ ID NO 1 er Ο,Ο-bundne phosphorthioater.
3. Farmaceutisk tabletformulering ifølge krav 1 eller 2, hvor antisense-oligonukleotidet er natriumsaltet af SEQ ID NO 1.
4. Farmaceutisk tabletformulering ifølge et hvilket som helst af kravene 1-3, hvor den intra-granulære fase yderligere omfatter et disintegrant og/eller den ekstra-granulære fase yderligere omfatter enlubrikant.
5. Farmaceutisk tabletformulering ifølge krav 4, hvor lubrikanten er natriumstivelsesglycolat.
6. Farmaceutisk tabletformulering ifølge et hvilket som helst af kravene 1-5, hvor fyldstoffet er mannitol, og/eller disintegranteter natriumstivelsesglycolat.
7. Farmaceutisk tabletformulering ifølge et hvilket som helst af kravene 1-6, hvor den intra-granulære fase yderligere omfatter en komponent valgt fra mikrokrystallinsk cellulose, natriumstivelsesglycolat, hydroxypropylmethyl cellulose, og blandinger deraf og/eller den ekstra-granulære fase yderligere omfatter en komponent valgt fra mikrokrystallinsk cellulose og magnesiumstearat, og blandinger deraf.
8. Farmaceutisk tabletformulering ifølge et hvilket som helst af kravene 1-7 hvor den enteriske coating er 8 til 18%, af tablettens vægt.
9. Farmaceutisk tabletformulering ifølge krav 1 omfattende: 0,5 til 10 vægtprocent af et antisense-oligonukleotid vist med SEQ ID NO 1 eller et farmaceutisk acceptabelt salt deraf; 30 til 50 vægtprocent mannitol; og 10 til 30 vægtprocent mikrokrystallinsk cellulose.
10. Farmaceutisk tabletformulering ifølge krav 1 omfattende 35 mg til 500 mg af antisense-oligonukleotidet vist med SEQ ID NO 1 eller et farmaceutisk acceptabelt salt deraf.
11. Farmaceutisk tabletformulering ifølge krav 1 omfattende: en intra-granulær fase omfattende: 5 til 10 vægtprocent antisense-oligonukleotidet vist med SEQ ID NO 1 eller et farmaceutisk acceptabelt salt deraf; ca. 40 vægtprocent mannitol, ca. 8 vægtprocent mikrokrystallinsk cellulose, ca. 5 vægtprocent hydroxypropylmethyl cellulose, og ca. 2 vægtprocent natriumstivelsesglycolat; og en ekstra-granulær fase omfattende: ca. 17 vægtprocent mikrokrystallinsk cellulose, ca. 2 vægtprocent natriumstivelsesglycolat, og ca. 0,4 vægtprocent magnesiumstearat.
12. Farmaceutisk tabletformulering ifølge krav 10, med ca. 40 mg af antisense-nukleotidet.
13. Farmaceutisk tabletformulering ifølge et hvilket som helst af kravene 1-12 til anvendelse i behandling af Crohn's sygdom, ulcerativ colitis eller kronisk inflammatorisk tarmsygdom.
14. Farmaceutisk tabletformulering ifølge krav 1, hvor den farmaceutiske tabletformulering omfatter 0,5 til 70 vægtprocent af et antisense-oligonukleotid vist med SEQ ID NO: 1 eller et farmaceutisk acceptabelt salt deraf; 0,5 til 60 vægtprocent mannitol; 20 til 40 vægtprocent mikrokrystallinsk cellulose.
15. Farmaceutisk tabletformulering ifølge krav 14, hvor den farmaceutiske tabletformulering omfatter 5 til 20 vægtprocent af den enteriske coating.
16. Farmaceutisk tabletformulering ifølge krav 14, hvor den farmaceutiske tabletformulering omfatter 8 til 18 vægtprocent af den enteriske coating.
17. Farmaceutisk tabletformulering ifølge krav 14, hvor den farmaceutiske tabletformulering omfatter 8 til 15 vægtprocent af den enteriske coating.
18. Farmaceutisk tabletformulering ifølge krav 14, hvor den farmaceutiske tabletformulering omfatter 12 til 16 vægtprocent af den enteriske coating.
19. Farmaceutisk tabletformulering ifølge krav 14, hvor den farmaceutiske tabletformulering omfatter ca. 13%, ca. 15%, ca. 16%, eller ca. 17 vægtprocent af den enteriske coating.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08425727 | 2008-11-13 | ||
US15229709P | 2009-02-13 | 2009-02-13 | |
PCT/EP2009/008087 WO2010054826A1 (en) | 2008-11-13 | 2009-11-13 | Antisense compositions and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2364360T3 true DK2364360T3 (da) | 2017-06-19 |
Family
ID=42101499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09756431.4T DK2364360T3 (da) | 2008-11-13 | 2009-11-13 | Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf |
Country Status (21)
Country | Link |
---|---|
US (7) | US8912154B2 (da) |
EP (2) | EP2364360B1 (da) |
JP (7) | JP5719776B2 (da) |
KR (2) | KR101767145B1 (da) |
CN (2) | CN102216458B (da) |
AU (4) | AU2009315898B2 (da) |
CA (2) | CA2743329C (da) |
CY (1) | CY1119140T1 (da) |
DK (1) | DK2364360T3 (da) |
ES (1) | ES2627745T3 (da) |
HR (1) | HRP20170926T1 (da) |
HU (1) | HUE032368T2 (da) |
LT (1) | LT2364360T (da) |
MX (3) | MX346335B (da) |
NZ (1) | NZ592673A (da) |
PL (1) | PL2364360T3 (da) |
PT (1) | PT2364360T (da) |
RS (1) | RS56049B1 (da) |
RU (2) | RU2739302C2 (da) |
SI (1) | SI2364360T1 (da) |
WO (1) | WO2010054826A1 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
CA2743329C (en) | 2008-11-13 | 2020-09-01 | Giuliani International Limited | Antisense compositions and methods of making and using same |
CN104040349B (zh) | 2011-09-15 | 2017-07-04 | 诺格尔制药有限公司 | 用于监测对抗smad7疗法的反应性的方法 |
ITCO20120008A1 (it) * | 2012-03-01 | 2013-09-02 | Nuovo Pignone Srl | Metodo e sistema per monitorare la condizione di un gruppo di impianti |
WO2013158868A1 (en) | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
US20140122184A1 (en) * | 2012-10-29 | 2014-05-01 | Elwha Llc | Food Supply Chain Automation Grocery Information System And Method |
WO2014110225A1 (en) * | 2013-01-09 | 2014-07-17 | The Feinstein Institute For Medical Research | Hmgb1-binding beads and uses thereof |
US10006029B2 (en) * | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
CA2903597C (en) * | 2013-03-15 | 2023-04-04 | Nogra Pharma Limited | Methods of treating colorectal cancer |
MX2016014624A (es) * | 2014-05-09 | 2017-05-25 | Nogra Pharma Ltd | Metodos para el tratamiento de enfermedad inflamatoria del intestino. |
US20170233736A1 (en) * | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
AU2015332624A1 (en) | 2014-10-17 | 2017-05-04 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
WO2015011694A2 (en) | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues of smad7 antisense oligonucleotides |
MA41271A (fr) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
JP6583954B2 (ja) * | 2015-01-08 | 2019-10-02 | 日東電工株式会社 | 展示装置および映像展示方法 |
US9688993B2 (en) | 2015-02-13 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
JP2018531936A (ja) * | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてsmad7アンチセンスオリゴヌクレオチドを使用する方法 |
MA44309A (fr) | 2015-11-25 | 2018-10-03 | Nogra Pharma Ltd | Oligonucléotides antisens il-34 et leurs procédés d'utilisation |
WO2017147276A1 (en) * | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
EP3419616A1 (en) | 2016-02-26 | 2019-01-02 | Nogra Pharma Limited | Methods of treating lactose intolerance |
WO2018111323A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease |
WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
WO2018122376A1 (en) | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
GB201707501D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New therapy 2 |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
EP3914227A1 (en) | 2019-01-25 | 2021-12-01 | Nogra Pharma Limited | Compositions for use in preventing acne |
MX2021010255A (es) | 2019-02-26 | 2021-12-15 | Nogra Pharma Ltd | Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos. |
MX2022005900A (es) | 2019-11-15 | 2022-06-24 | Nogra Pharma Ltd | Agentes antisentido de il-34 y metodos de uso de los mismos. |
WO2022243299A1 (en) | 2021-05-17 | 2022-11-24 | Nogra Pharma Limited | Il-34 antisense agents and methods of using same |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
IT1230576B (it) | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
JP3499562B2 (ja) | 1993-09-24 | 2004-02-23 | アドヴァンスト・イミューニット・インク | Crohn’s病および/または潰瘍性大腸炎の治療もしくは予防 |
AU3404997A (en) | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
KR20010020370A (ko) | 1997-04-30 | 2001-03-15 | 파샬 비. 린네 | 향상된 생체이용률을 갖는 올리고뉴클레오티드 |
IE970794A1 (en) * | 1997-09-24 | 2000-08-23 | Elan Corp Plc | Composition and method for enhancing paracellular transport across cell layers |
PT1017404E (pt) | 1997-09-26 | 2004-11-30 | Celltech Pharma Europ Ltd | Formulacao farmaceutica para o tratamento de doenca inflamatoria do intestino |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
JPH11335269A (ja) * | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
WO1999060012A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
PT1456380E (pt) | 2001-11-02 | 2012-07-23 | Giuliani Int Ltd | Inibidores smad7 para o tratamento de doenças do snc |
ZA200502318B (en) * | 2002-10-16 | 2006-11-29 | Takeda Pharmaceutical | Controlled release preparation |
US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
AR045076A1 (es) * | 2003-07-24 | 2005-10-12 | Smithkline Beecham Plc | Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se |
ITRM20030393A1 (it) | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
RU2375047C2 (ru) * | 2004-03-26 | 2009-12-10 | Лек Фармасьютиклз Д.Д. | Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423) |
US20070243249A1 (en) | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
CN101151035A (zh) * | 2004-12-02 | 2008-03-26 | Isis制药公司 | 用于治疗炎性肠病的治疗性反义寡核苷酸组合物 |
US20060258610A1 (en) * | 2005-05-12 | 2006-11-16 | Isis Pharmaceuticals, Inc. | Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness |
JP2009502957A (ja) | 2005-07-28 | 2009-01-29 | スパーナス ファーマシューティカルズ インコーポレイテッド | 機械的特性の向上した徐放性錠剤配合物 |
WO2007047553A2 (en) | 2005-10-14 | 2007-04-26 | Zweig Jack I | Methods and compositions for treatment of prostate intraepithelial neoplasia |
CN1850135A (zh) * | 2006-03-09 | 2006-10-25 | 陈世忠 | 一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用 |
GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
JP2010523554A (ja) * | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | タクロリムスの医薬組成物 |
CA2743329C (en) | 2008-11-13 | 2020-09-01 | Giuliani International Limited | Antisense compositions and methods of making and using same |
US9364495B2 (en) * | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
CN104040349B (zh) | 2011-09-15 | 2017-07-04 | 诺格尔制药有限公司 | 用于监测对抗smad7疗法的反应性的方法 |
WO2013158868A1 (en) | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
CA2903597C (en) | 2013-03-15 | 2023-04-04 | Nogra Pharma Limited | Methods of treating colorectal cancer |
US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
MX2016014624A (es) | 2014-05-09 | 2017-05-25 | Nogra Pharma Ltd | Metodos para el tratamiento de enfermedad inflamatoria del intestino. |
MA40406A (fr) | 2014-07-28 | 2016-02-04 | Nogra Pharma Ltd | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin |
AU2015332624A1 (en) | 2014-10-17 | 2017-05-04 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
JP2018531936A (ja) | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてsmad7アンチセンスオリゴヌクレオチドを使用する方法 |
WO2017144689A1 (en) | 2016-02-24 | 2017-08-31 | Nogra Pharma Limited | Methods of treating celiac disease using smad7 inhibition |
WO2018122376A1 (en) | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2009
- 2009-11-13 CA CA2743329A patent/CA2743329C/en active Active
- 2009-11-13 CN CN200980145188.6A patent/CN102216458B/zh active Active
- 2009-11-13 PL PL09756431T patent/PL2364360T3/pl unknown
- 2009-11-13 HU HUE09756431A patent/HUE032368T2/en unknown
- 2009-11-13 AU AU2009315898A patent/AU2009315898B2/en active Active
- 2009-11-13 DK DK09756431.4T patent/DK2364360T3/da active
- 2009-11-13 EP EP09756431.4A patent/EP2364360B1/en active Active
- 2009-11-13 EP EP16187284.1A patent/EP3121280A1/en active Pending
- 2009-11-13 MX MX2015003911A patent/MX346335B/es unknown
- 2009-11-13 PT PT97564314T patent/PT2364360T/pt unknown
- 2009-11-13 MX MX2011005042A patent/MX2011005042A/es active IP Right Grant
- 2009-11-13 KR KR1020117013391A patent/KR101767145B1/ko active IP Right Grant
- 2009-11-13 ES ES09756431.4T patent/ES2627745T3/es active Active
- 2009-11-13 RU RU2016127232A patent/RU2739302C2/ru active
- 2009-11-13 RU RU2011123876/10A patent/RU2593939C2/ru active
- 2009-11-13 NZ NZ592673A patent/NZ592673A/xx unknown
- 2009-11-13 LT LTEP09756431.4T patent/LT2364360T/lt unknown
- 2009-11-13 KR KR1020177021816A patent/KR101921014B1/ko active IP Right Grant
- 2009-11-13 SI SI200931677T patent/SI2364360T1/sl unknown
- 2009-11-13 CA CA3085272A patent/CA3085272A1/en active Pending
- 2009-11-13 RS RS20170564A patent/RS56049B1/sr unknown
- 2009-11-13 WO PCT/EP2009/008087 patent/WO2010054826A1/en active Application Filing
- 2009-11-13 CN CN201710263782.1A patent/CN107007616A/zh active Pending
- 2009-11-13 JP JP2011535922A patent/JP5719776B2/ja active Active
- 2009-11-13 US US13/129,205 patent/US8912154B2/en active Active
-
2011
- 2011-05-12 MX MX2023008408A patent/MX2023008408A/es unknown
-
2014
- 2014-07-16 JP JP2014145605A patent/JP2014196356A/ja not_active Withdrawn
- 2014-12-15 US US14/570,313 patent/US9499819B2/en active Active
- 2014-12-15 US US14/570,293 patent/US9314434B2/en active Active
-
2015
- 2015-09-16 JP JP2015182496A patent/JP6095744B2/ja active Active
- 2015-10-21 AU AU2015246097A patent/AU2015246097B2/en active Active
-
2016
- 2016-04-15 US US15/130,737 patent/US9982264B2/en active Active
- 2016-10-26 US US15/335,198 patent/US10272047B2/en active Active
-
2017
- 2017-02-03 JP JP2017018231A patent/JP6530772B2/ja active Active
- 2017-06-12 CY CY20171100611T patent/CY1119140T1/el unknown
- 2017-06-16 HR HRP20170926TT patent/HRP20170926T1/hr unknown
- 2017-12-19 AU AU2017279624A patent/AU2017279624B2/en active Active
-
2019
- 2019-01-15 US US16/248,414 patent/US20190374472A1/en not_active Abandoned
- 2019-05-17 JP JP2019093866A patent/JP7377624B2/ja active Active
-
2020
- 2020-04-29 AU AU2020202813A patent/AU2020202813A1/en not_active Abandoned
-
2021
- 2021-01-29 US US17/162,226 patent/US20210290656A1/en active Pending
- 2021-06-21 JP JP2021102423A patent/JP2021138778A/ja active Pending
-
2023
- 2023-08-09 JP JP2023130212A patent/JP2023138750A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210290656A1 (en) | Antisense Compositions and Methods of Making and Using Same | |
CN108606956A (zh) | 用于治疗唾液酸缺乏的方法和制剂 |